Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 2162 Download: 171 Web of Science: 1 Crossref: 2

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(Suppl):S165-181. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855

View: 2547 Download: 379 Web of Science: 4 Crossref: 7

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning

Clin Mol Hepatol. 2025;31(Suppl):S134-S164. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.0780

View: 3198 Download: 386 Crossref: 1

Correspondence

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(2):e169-e172. Published online December 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.1138

View: 878 Download: 26

Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2025;31(2):e149-e151. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0944

View: 966 Download: 20

Letter to the Editor

Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(2):e140-e142. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0960

View: 929 Download: 30 Web of Science: 1 Crossref: 1

Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”

Chunlong Liu, Jiangtao Yu

Clin Mol Hepatol. 2025;31(2):e134-e136. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1085

View: 1219 Download: 85 Crossref: 1

Editorial

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Chih-Wen Wang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.1078

View: 1131 Download: 32 Web of Science: 1 Crossref: 1

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Robert J. Wong

Clin Mol Hepatol. 2025;31(2):603-605. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0929

View: 854 Download: 27 Web of Science: 1 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):e117-e118. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0994

View: 947 Download: 21

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0867

View: 1217 Download: 33

Correspondence

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 1120 Download: 34

Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Young-Joo Jin, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e55-e57. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0846

View: 1026 Download: 21 Crossref: 1

Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer

Clin Mol Hepatol. 2025;31(1):e44-e47. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0781

View: 1279 Download: 45 Crossref: 1

Letter to the Editor

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 1211 Download: 52 Crossref: 1

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs

Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e19-e20. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0906

View: 977 Download: 35

Editorial

The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):268-274. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0817

View: 1332 Download: 52 Crossref: 2

Original Article

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640

View: 2005 Download: 165 Web of Science: 4

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(1):105-118. Published online July 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198

View: 3715 Download: 329 Web of Science: 5 Crossref: 2

Letter to the Editor

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults

Donghee Kim, Won Kim, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0849

View: 1087 Download: 43 Web of Science: 1 Crossref: 1

Original Article

Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis

Young-Joo Jin, Hee Yeon Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun, Miyoung Choi, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S159-S171. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0163

View: 2385 Download: 124 Web of Science: 7 Crossref: 4

Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis

Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi

Clin Mol Hepatol. 2024;30(Suppl):S106-S116. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0371

View: 2367 Download: 113 Web of Science: 4 Crossref: 5

Reply to Correspondence

Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):1053-1054. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0572

View: 1826 Download: 48 Web of Science: 1 Crossref: 1

Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):1044-1046. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0584

View: 1360 Download: 28

Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”

Pin-Nan Cheng, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):1031-1032. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0228

View: 1941 Download: 63

Correspondence

Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2024;30(4):997-999. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0588

View: 1437 Download: 45

Original Article

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

Clin Mol Hepatol. 2024;30(4):793-806. Published online July 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0252

View: 3122 Download: 215 Web of Science: 8 Crossref: 10

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 4208 Download: 363 Web of Science: 7 Crossref: 10

Editorial

Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):724-727. Published online July 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0465

View: 1820 Download: 75 Web of Science: 1 Crossref: 1

Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study”

Yewan Park, Dong Hyun Sinn

Clin Mol Hepatol. 2024;30(4):718-720. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0519

View: 1528 Download: 71

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |

Viewed By 11947	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7478	MAFLD: How is it different from NAFLD?
Viewed By 6568	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5734	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5352	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 355	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 331	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 223	MAFLD: How is it different from NAFLD?
Cited By 114	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search